Inflammatory Conditions - Tocilizumab Intravenous Products Utilization Management Medical Policy
Customize your policy alerts
Sign up for UCare POLICY: Inflammatory Conditions - Tocilizumab Intravenous Products Utilization Management Medical Policy alerts
Get alerted when POLICY: Inflammatory Conditions - Tocilizumab Intravenous Products Utilization Management Medical Policy changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, step-therapy, and medical necessity criteria for intravenous tocilizumab products (Actemra, Avtozma, Tofidence) for UCare medical plans; excludes acute inpatient COVID-19 treatment. Affects prescribers, prior auth reviewers, and plan members.
Cytokine Release Syndrome associated with bispecific antibodies was added as a condition of approval.
Step therapy was updated to require chart note documentation of medical necessity for non-preferred products and Tyenne designated preferred for new-to-therapy patients.
Giant cell arteritis corticosteroid requirement changed to 'tried or currently taking' a systemic corticosteroid unless contraindicated.
Acute COVID-19 treatment in hospitalized patients is not addressed in this policy and COVID-19 generally is listed among conditions not recommended for approval.
Recommended Authorization Criteria
Cytokine Release Syndrome (CAR T-cell therapy)
Covered when ALL of the following are met
CRS Indication and Dosing
- Dosing: Each individual dose meets weight-based dosing: if < 30 kg: up to 12 mg/kg to a maximum 800 mg per dose; if >= 30 kg: up to 8 mg/kg to a maximum 800 mg per dose
- Number of doses and interval: Approve up to four dosesThere must be an interval of at least 8 hours between doses
Giant Cell Arteritis
Covered when ONE of the following is met
Initial or Continuation
- Initial Therapy: Patient > 18 years of age AND tried or is currently taking a systemic corticosteroid (or systemic corticosteroids are contraindicated) AND medication is prescribed by or in consultation with a rheumatologistApprove for 6 months
- Currently Receiving: Patient has been established on tocilizumab therapy for at least 6 months AND meets at least ONE of: a) objective measure shows beneficial clinical response from baseline; OR b) improvement in at least one symptom compared with baseline (e.g., decreased headache, scalp or jaw pain; decreased fatigue; improved vision)Approve for 1 year
Polyarticular Juvenile Idiopathic Arthritis
Covered when ONE of the following is met
Initial or Continuation
- Initial Therapy: Patient > 2 years of age AND meets ONE of prior systemic therapy conditions: a) tried one other systemic therapy (e.g., methotrexate, sulfasalazine, leflunomide, or an NSAID or biologic) OR b) starting tocilizumab concurrently with methotrexate/sulfasalazine/leflunomide OR c) absolute contraindication to methotrexate/sulfasalazine/leflunomide OR d) aggressive disease as determined by prescriber; AND medication is prescribed by or in consultation with a rheumatologistApprove for 6 months
- Currently Receiving: Patient has been established on tocilizumab therapy for at least 6 months AND meets at least ONE of: a) when assessed by at least one objective measure, experienced a beneficial clinical response from baseline (examples: MD global, PGA, JADAS, cJADAS, JSpADA, serum markers such as CRP/ESR, or reduced corticosteroid dose) OR b) improvement in at least one symptom compared with baseline (e.g., improved function, less joint pain)Approve for 1 year
Rheumatoid Arthritis
Covered when ONE of the following is met
Initial or Continuation
- Initial Therapy: Patient > 18 years of age AND tried one conventional synthetic DMARD for at least 3 months (exceptions if prior biologic trial) AND medication is prescribed by or in consultation with a rheumatologistApprove for 6 months
- Currently Receiving: Patient has been established on tocilizumab therapy for at least 6 months AND meets at least ONE of: a) objective measure shows beneficial clinical response from baseline (e.g., CDAI, DAS28-ESR/CRP, RAPID-3, SDAI) OR b) improvement in at least one symptom compared with baseline (e.g., decreased joint pain, morning stiffness, improved function)Approve for 1 year
Systemic Juvenile Idiopathic Arthritis / Still's disease
Covered when ONE of the following is met
Initial or Continuation
- Initial Therapy: Patient > 2 years of age (for sJIA) AND medication is prescribed by or in consultation with a rheumatologistApprove for 6 months
- Currently Receiving: Patient has been established on tocilizumab therapy for at least 6 months AND meets at least ONE of: a) objective measure shows beneficial clinical response from baseline (e.g., resolution of fever, improvement in rash, normalization of CRP/ESR) OR b) improvement in at least one symptom compared with baseline (e.g., less joint pain/tenderness, decreased fatigue)Approve for 1 year
Castleman Disease
Covered when ONE of the following is met
Initial or Continuation
- Initial Approval: Patient > 18 years of age AND HIV negative AND HHV8 negative AND medication is being used for relapsed or refractory Castleman disease AND medication is prescribed by or in consultation with an oncologist or hematologistApprove for 6 months
- Currently Receiving: Patient has been established on tocilizumab therapy for at least 6 months AND meets at least ONE of: a) objective measure shows beneficial clinical response from baseline (e.g., CRP, ESR, fibrinogen, albumin, hemoglobin, increased BMI, reduction in lymphadenopathy) OR b) improvement in at least one symptom from baseline (e.g., resolution of constitutional symptoms)Approve for 1 year
Initial vs Continuation (FDA-approved)
Covered when the following grouped criteria are met for FDA-approved indications
Castleman Disease
Covered for Castleman disease when either initial or continuation criteria met
Cytokine Release Syndrome (bispecific antibodies)
Covered when used for CRS associated with bispecific antibody treatment
Approve for 1 week (up to four doses)
Graft-Versus-Host Disease
Covered for acute graft-versus-host disease when indications met
Immunotherapy-related Toxicities (checkpoint inhibitors)
Covered for immunotherapy-related toxicities when criteria met
Polymyalgia Rheumatica
Covered for polymyalgia rheumatica when criteria met
Still's Disease (AOSD)
Covered for adult-onset Still's disease when criteria met
The policy does not address the acute treatment of COVID-19 in hospitalized patients. Prior authorization recommendations and the listed coverage criteria apply to the conditions and dosing described in this policy; decisions about acute inpatient COVID-19 therapy are outside this policy's scope.
For UCare, coverage of tocilizumab intravenous products for acute COVID-19 treatment in hospitalized patients is not addressed in this policy. The policy notes that tocilizumab IV is indicated for hospitalized adults with COVID-19 only under specific clinical circumstances per prescribing information, but acute inpatient COVID-19 treatment is excluded from the authorization criteria documented here.
Concurrent administration of tocilizumab with another biologic agent or with a targeted synthetic oral small molecule used for inflammatory conditions is not recommended. The policy explains combination therapy generally is discouraged because of increased adverse event risk and limited evidence for additive benefit.
The policy appendix is presented as an informational list and explicitly states it is not an all‑inclusive list of indications. Providers are directed to consult the respective prescribing information for the full set of FDA‑approved indications; the appendix excerpts do not provide explicit exclusions beyond that note.
Continuation overrides cannot be used to bypass required trials of a preferred biosimilar or biologic reference product. Requests that do not document adequate trials, adverse reactions, or other accepted exceptions may be considered not medically necessary for purposes of authorization.
The policy states that coverage is not recommended for indications or circumstances not listed in the Recommended Authorization Criteria. An example called out is Crohn's disease, for which available evidence was judged insufficient to support routine approval under this policy.
In the appendix excerpts provided, there are no explicit statements labeling specific entries as 'not medically necessary'. The appendix instead advises referral to prescribing information and presents an informational, non‑exhaustive listing of agents and example indications.
Product and Dosing Codes / Key Dosing Rules
| NDC not listed | No NDCs listed in this portion of the document |
| N/A | No explicit CPT/HCPCS/ICD-10 codes listed in this document fragment. |
Prior Authorization, Step Therapy, and Documentation Requirements
Prior Authorization Required
Prior authorization is recommended for medical benefit coverage of tocilizumab intravenous products. A preferred biosimilar step is required for patients new to therapy: Tyenne is the preferred product and must be tried before non-preferred tocilizumab products (Actemra, Avtozma, Tofidence) will be authorized unless one of the Step Therapy exceptions A–D is met. Requests for non-preferred biologic products or biosimilars will be granted only if the patient has documented clinical need (one of the exceptions below) for the non-preferred product versus all preferred product(s). Chart notes documenting the required trial, adverse reaction, allergy, or therapeutic response must be provided at the time of request. Because of the specialized skills required for evaluation and monitoring, initial approval requires the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated (e.g., rheumatologist, oncologist/hematologist, transplant-affiliated physician). No other step therapy requirements are specified in the appendix excerpts.
- Preferred product: Tyenne (preferred biosimilar)
- Non-preferred products: Actemra, Avtozma, Tofidence
- Prior authorization: Recommended for tocilizumab IV products; approvals provided when criteria met
- Initial prescriber requirement: Must be prescribed by or in consultation with a specialist in the treated condition
Preferred Product Step (Exceptions Required to Use Non-Preferred)
Authorization for a non-preferred biologic product or biosimilar will be granted ONLY if the patient has had one of the following issues with ALL preferred product(s). Chart notes documenting the issue must be provided at time of request:
- A. Documented allergic reaction to a specific inactive ingredient in all preferred biologic products or biosimilars
- B. Documented adverse reaction to a specific inactive ingredient in all preferred biologic products or biosimilars
- C. Therapeutic success while taking a non-preferred biologic product or biosimilar AND therapeutic failure during an adequate trial of all preferred biologic products or biosimilars (adequate trial generally considered ≥3 months) — documentation of therapeutic response/failure required in chart notes
- D. The patient has a diagnosis that is not included in the FDA‑approved indications of all preferred products but is included in the FDA‑approved indications of the non-preferred product
Requests for Non-Preferred Biologic Products
Requests for non-preferred biologic products will be denied unless the member has documented allergy or adverse reaction to all preferred products, documented therapeutic failure after an adequate trial of all preferred products (with supporting chart notes), documented therapeutic success on the non-preferred product with failure on preferred products, or the non-preferred product covers an FDA‑approved indication not available with all preferred products. Patient or prescriber preference, or a facility/pharmacy's inability or unwillingness to stock the preferred product, are not acceptable reasons for approval. Continuation-of-therapy overrides are not available to bypass required trials of preferred biosimilar or reference products.
- Denial risk if step requirements are not met
- Patient/prescriber preference or stocking issues are not acceptable exceptions
- Continuation overrides do not bypass required preferred-product trials
Required Documentation
Chart notes documenting prior trials, adverse reactions, allergies, or therapeutic response must be submitted with the prior authorization request. Prescriber specialty or consultation must be documented (e.g., rheumatologist, oncologist/hematologist, transplant-affiliated physician). Documentation should include dates, duration of trials, objective measures of response when available (e.g., CRP, ESR, symptom change), and rationale when requesting a non-preferred product.
- Required documentation: chart notes showing trials, adverse reactions, allergies, or therapeutic response
- Prescriber specialty or consultation documentation required (e.g., rheumatologist, oncologist/hematologist)
- Objective measures (CRP, ESR, symptom improvement) encouraged to demonstrate benefit or failure
Appendix / Step Therapy Scope
No additional step therapy requirements are specified in the policy appendix excerpts beyond the preferred biosimilar step for new-to-therapy patients (Tyenne preferred before Actemra and Tofidence). The appendix lists agents, formulations, mechanisms, and example indications for informational purposes and does not itself create further step requirements.
- Appendix informational: lists agents, mechanisms, and example indications
- No other step therapy rules are specified in the appendix excerpts
Clinical and Policy Context
Tocilizumab is an interleukin‑6 (IL‑6) receptor inhibitor indicated for multiple inflammatory and immune‑mediated conditions, including cytokine release syndrome associated with CAR T‑cell therapy, giant cell arteritis, polyarticular and systemic juvenile idiopathic arthritis, rheumatoid arthritis, and others. Dosing, monitoring, and approval durations vary by indication, and initial approvals generally require specialist prescribing or consultation and prior authorization.
Terms and Product Definitions
Policy Changes and Version History
Avtozma was added to the policy with the same criteria as other tocilizumab intravenous products.
Policy reviewed and approved by the UCare P&T committee as part of the annual review process.
Cytokine release syndrome associated with bispecific antibodies was added as a condition of approval; graft-versus-host disease was added; immunotherapy-related toxicities criteria were expanded and specialist requirements updated.
Treatment of COVID-19 in a non-hospitalized patient was revised to more generally state COVID-19; other clarifications made to indications and requirements.
Annual review with no clinical criteria changes noted in the summary of changes.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.